Colocalization of ovarian cancer-associated biomarkers in tumors, cancer cells and extracellular vesicles.
Poster Co-presented with Mercy BioAnalytics. AACR, 2024.
Moderna CoView
Acknowledged in presentation by Moderna. Moderna Fourth Annual Science Day, 2021
Transplanted organoids empower human preclinical assessment of drug candidate for the clinic.
Co-authored with Goldfinch Therapeutics. Science Advances, 2022.
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.
Co-authored with Foghorn Therapeutics. Clinical Cancer Research, 2025.
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Acknowledged in paper by Cartesian Therapeutics. Nature Medicine, 2026.
Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies
Oral presentation co-authored with Foghorn Therapeutics. ASH, 2025.
Nonhuman Primate Genomes Have Limited Relevance for Evaluating Human CRISPR Off-Target Effects.
Co-authored with Sanofi's Genomic Medicine Unit. Human Gene Therapy.
2026;0(0) 2026
paper link
You must be logged in to post a comment.